

# Ronac Mamtani, Msce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6351637/publications.pdf>

Version: 2024-02-01

119  
papers

5,819  
citations

147801

31  
h-index

82547

72  
g-index

123  
all docs

123  
docs citations

123  
times ranked

10058  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	1.4	829
2	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. <i>Science</i> , 2021, 371, 602-609.	12.6	784
3	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. <i>Nature Medicine</i> , 2021, 27, 1280-1289.	30.7	365
4	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 931-945.	10.7	337
5	Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 265.	7.4	263
6	Recurrent antibiotic exposure may promote cancer formation – Another step in understanding the role of the human microbiota?. <i>European Journal of Cancer</i> , 2015, 51, 2655-2664.	2.8	233
7	Antibiotic Exposure and the Risk for Depression, Anxiety, or Psychosis. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1522-1528.	2.2	169
8	Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity. <i>Gastroenterology</i> , 2016, 151, 120-129.e5.	1.3	145
9	A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. <i>Gastroenterology</i> , 2017, 152, 840-850.e3.	1.3	133
10	The effect of past antibiotic exposure on diabetes risk. <i>European Journal of Endocrinology</i> , 2015, 172, 639-648.	3.7	131
11	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016, 152, 164.	4.1	131
12	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016, 151, 97-109.e4.	1.3	120
13	Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1411-1421.	6.3	105
14	Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor- $\alpha$ -Directed Therapy for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 405-417.	0.4	99
15	Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e1921653.	5.9	97
16	Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis. <i>Cancer</i> , 2016, 122, 693-701.	4.1	87
17	Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3575-3581.	1.6	76
18	Impact of antibiotic exposure on the risk of colorectal cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 534-542.	1.9	73

#	ARTICLE	IF	CITATIONS
19	Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Cancer Institute</i> , 2019, 111, 490-497.	6.3	69
20	Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. <i>Diabetes Care</i> , 2014, 37, 1910-1917.	8.6	64
21	Liver transplant center variability in accepting organ offers and its impact on patient survival. <i>Journal of Hepatology</i> , 2016, 64, 843-851.	3.7	62
22	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. <i>PLoS Medicine</i> , 2016, 13, e1002007.	8.4	55
23	Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the <sc>N</sc>ational <sc>C</sc>ancer <sc>D</sc>ata <sc>B</sc>ase. <i>Cancer</i> , 2014, 120, 2855-2865.	4.1	54
24	Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. <i>Cancer</i> , 2017, 123, 794-801.	4.1	51
25	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1012-1016.	0.9	48
26	Association Between <i>KRAS</i> Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 937.	7.1	48
27	Thyroid Dysfunction, Thyroid Hormone Replacement and Colorectal Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv084.	6.3	46
28	Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 524-532.	1.9	38
29	Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2403-2411.	5.6	36
30	Associations Between Travel Distance, Hospital Volume, and Outcomes Following Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer. <i>Urology</i> , 2018, 114, 87-94.	1.0	36
31	The Benefit-to-Risk Balance of Combining Infliximab With Azathioprine Varies With Age: A Markov Model. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 302-309.e11.	4.4	35
32	Increasing use of prescription drugs in the United Kingdom. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 628-636.	1.9	35
33	Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. <i>Oncologist</i> , 2019, 24, e397-e399.	3.7	33
34	Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. <i>European Journal of Cancer</i> , 2018, 94, 1-5.	2.8	31
35	Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2262-2268.	4.4	31
36	Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 636-645.	1.9	26

#	ARTICLE	IF	CITATIONS
37	Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data. <i>Cancer</i> , 2019, 125, 406-415.	4.1	26
38	Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa120.	2.9	26
39	Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. <i>JAMA Oncology</i> , 2021, 7, 1843.	7.1	26
40	Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States. <i>Annals of Surgery</i> , 2016, 263, 298-305.	4.2	25
41	Distinguishing incident and prevalent diabetes in an electronic medical records database. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 111-118.	1.9	23
42	Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 363-369.	2.5	23
43	Anti-depressant therapy and cancer risk: A nested case-control study. <i>European Neuropsychopharmacology</i> , 2015, 25, 1147-1157.	0.7	21
44	Parkinson's disease and colorectal cancer risk: A nested case control study. <i>Cancer Epidemiology</i> , 2016, 43, 9-14.	1.9	20
45	Impact of metformin on the progression of MGUS to multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1265-1267.	1.3	20
46	Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1209.	7.4	20
47	Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. <i>European Journal of Cancer</i> , 2016, 59, 90-98.	2.8	19
48	Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States. <i>Annals of Surgical Oncology</i> , 2016, 23, 2936-2945.	1.5	19
49	Incidence, Risk Factors, and Clinical Effects of Recurrent Diverticular Hemorrhage: A Large Cohort Study. <i>Gastroenterology</i> , 2018, 155, 1416-1427.	1.3	19
50	Functional imaging of the interaction between gut microbiota and the human host: A proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT. <i>PLoS ONE</i> , 2018, 13, e0192747.	2.5	19
51	Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 531-541.	4.9	18
52	Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018. <i>JAMA Network Open</i> , 2020, 3, e2018318.	5.9	18
53	Digoxin use and the risk for colorectal cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1147-1153.	1.9	17
54	Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. <i>American Journal of Hematology</i> , 2016, 91, 581-584.	4.1	16

#	ARTICLE	IF	CITATIONS
55	A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, 33-38.	1.6	16
56	Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone. <i>JAMA Network Open</i> , 2022, 5, e2142093.	5.9	16
57	Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 326-336.	0.8	15
58	Validation of a Coding Algorithm to Identify Bladder Cancer and Distinguish Stage in an Electronic Medical Records Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 303-307.	2.5	15
59	Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. <i>Annals of Surgical Oncology</i> , 2015, 22, 863-872.	1.5	15
60	Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 318-321.	1.2	15
61	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Oncologist</i> , 2019, 24, 688-690.	3.7	15
62	Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1084-1091.	3.0	15
63	Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images. <i>Advances in Radiation Oncology</i> , 2018, 3, 331-338.	1.2	14
64	Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e17-e30.	1.9	14
65	Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction. <i>JAMA Network Open</i> , 2021, 4, e2036315.	5.9	14
66	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 967-977.	2.1	13
67	Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 599-604.	1.9	13
68	A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 149-155.	1.5	12
69	Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. <i>Cancer Medicine</i> , 2019, 8, 3698-3709.	2.8	12
70	Vinflunine in the treatment of advanced bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 13-20.	2.4	11
71	A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2076-2086.	2.3	11
72	Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 925-936.	1.9	11

#	ARTICLE	IF	CITATIONS
73	Association between age and sex and mortality after adjuvant therapy for renal cancer. <i>Cancer</i> , 2019, 125, 1637-1644.	4.1	11
74	Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. <i>European Urology Oncology</i> , 2020, 3, 663-670.	5.4	10
75	First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. <i>Future Oncology</i> , 2020, 16, 4341-4345.	2.4	10
76	Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa121.	2.9	10
77	Association of Itraconazole, a Hedgehog Inhibitor, and Bladder Cancer. <i>Journal of Urology</i> , 2016, 196, 343-348.	0.4	9
78	Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 217-226.	1.9	9
79	Disparities in resection of hepatic metastases in colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 126-134.	1.4	9
80	Height as an independent anthropomorphic risk factor for colorectal cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1422-1427.	1.6	8
81	Ayurveda and yoga in cardiovascular diseases. <i>Cardiology in Review</i> , 2005, 13, 155-62.	1.4	8
82	Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2022, 114, 571-578.	6.3	8
83	Angiosarcoma of the Bladder Following Prostate Radiotherapy. <i>American Journal of Medicine</i> , 2015, 128, e11-e12.	1.5	7
84	Pernicious anemia and colorectal cancer risk – A nested case-control study. <i>Digestive and Liver Disease</i> , 2016, 48, 1386-1390.	0.9	7
85	Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 235-239.	1.9	7
86	Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019, 18, 226-230.e2.	2.3	7
87	Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 575-587.	1.3	7
88	Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis. <i>Arthritis Care and Research</i> , 2023, 75, 260-271.	3.4	7
89	Granulomatosis and Testicular Germ Cell Tumors. <i>Urology</i> , 2012, 80, 1303-1306.	1.0	6
90	Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 121-129.	2.3	6

#	ARTICLE	IF	CITATIONS
91	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification—Defining novel predictive and prognostic markers in stage III colon cancer. <i>European Journal of Cancer</i> , 2018, 96, 105-110.	2.8	5
92	Posttraumatic Stress Disorder and Cancer Risk: A Nested Case–Control Study. <i>Journal of Traumatic Stress</i> , 2018, 31, 919-926.	1.8	5
93	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. <i>Oncologist</i> , 2019, 24, e671-e676.	3.7	5
94	Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn’s Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2082-2092.e10.	4.4	5
95	Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. <i>Journal of General Internal Medicine</i> , 2020, 35, 2826-2828.	2.6	5
96	Validation of a coding algorithm for intra-abdominal surgeries and adhesion-related complications in an electronic medical records database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 405-412.	1.9	4
97	The Association between Age-Related Macular Degeneration and Renal Cell Carcinoma: A Nested Case–Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 743-747.	2.5	4
98	Medication class enrichment analysis: a novel algorithm to analyze multiple pharmacologic exposures simultaneously using electronic health record data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 780-789.	4.4	3
99	Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer. <i>Urology</i> , 2019, 132, 143-149.	1.0	3
100	Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 136.e11-136.e17.	1.6	3
101	Bias reduction methods for propensity scores estimated from error-prone EHR-derived covariates. <i>Health Services and Outcomes Research Methodology</i> , 2021, 21, 169-187.	1.8	3
102	Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1503-1503.	1.6	3
103	An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case–control study. <i>Archives of Dermatological Research</i> , 2016, 308, 661-664.	1.9	2
104	Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?. <i>Molecular and Clinical Oncology</i> , 2019, 10, 555-559.	1.0	2
105	Adherence to and determinants of guideline–recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. <i>Cancer</i> , 2021, 127, 2562-2570.	4.1	2
106	'Considering the totality of evidence: Combining real–world data with clinical trial results to better inform decision–making. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 814-816.	1.9	2
107	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. <i>JCO Oncology Practice</i> , 2021, 17, e1879-e1886.	2.9	2
108	Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, e301-e309.	2.6	2

#	ARTICLE	IF	CITATIONS
109	Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy. <i>JAMA Oncology</i> , 2022, 8, 1070.	7.1	2
110	Ion channel blockers and glioblastoma risk and outcome: a nested case-control and retrospective cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1179-1185.	1.9	1
111	Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. <i>American Heart Journal</i> , 2020, 230, 54-58.	2.7	1
112	Digoxin use is associated with pancreatic cancer risk but does not affect survival. <i>Cancer Causes and Control</i> , 2021, 32, 41-46.	1.8	1
113	Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e111-e114.	3.7	1
114	Association between state Medicaid policies and accrual of Black participants to cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1501-1501.	1.6	1
115	Dr Lurie and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1654-e1654.	2.2	0
116	Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	0
117	Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma. <i>Cancer</i> , 2022, , .	4.1	0
118	Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2022, 40, 519-519.	1.6	0
119	Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6527-6527.	1.6	0